American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17–18, 2022

Author:

Kay Jonathan1ORCID,Nikolov Nikolay P.2ORCID,Weisman Michael H.3,

Affiliation:

1. UMass Chan Medical School and UMass Memorial Medical Center Worcester Massachusetts

2. Food and Drug Administration Center for Drug Evaluation and Research Silver Spring Maryland

3. Cedars‐Sinai Medical Center Los Angeles California

Abstract

The American College of Rheumatology and the US Food and Drug Administration co‐sponsored a public meeting in May 2022 about challenges in the clinical development of drugs for rheumatoid arthritis (RA) and psoriatic arthritis (PsA), focusing on innovative clinical trial designs, outcome measures, and data collection methods. Recommendations include early dose‐ranging studies and use of active comparators. Challenges and opportunities in assessing long‐term safety by leveraging real‐world data from electronic health records (EHRs) and claims data are discussed, along with insights from European registries and the evolving role of real‐world evidence and artificial intelligence in regulatory evaluations. Endpoints for assessing disease activity and outcome measures used in RA and PsA trials are explored, emphasizing challenges in defining remission, assessing clinical response, and evaluating structural progression. The need for outcome measures that better reflect treatment targets and the potential of advanced imaging in future trials are highlighted. Challenges with placebo‐controlled trials in RA are discussed and use of non‐inferiority clinical trial design, in which new drugs are evaluated with active comparators, is proposed. Pragmatic trials in RA and PsA, employing decentralized approaches, are highlighted for their real‐world relevance and administrative efficiencies. Strategies for identifying at‐risk populations for RA and the challenges of using EHRs and insurance claims data in drug development are discussed. Registry data and digital health technologies show promise in bridging the gap between clinical trials and real‐world effectiveness.

Publisher

Wiley

Reference69 articles.

1. American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010

2. Guidance for industry. Rheumatoid arthritis: developing drug products for treatment;US Food and Drug Administration;Draft Guidance.,2013

3. Guidance for industry;US Food and Drug Administration;Premarketing risk assessment.,2005

4. The Rule of Three, its Variants and Extensions

5. US Food and Drug Administration.Real‐world evidence. February 5 2023. Accessed March 4 2024.https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3